Related Experiment Video
Updated: Aug 11, 2026
The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
Published on: August 3, 2011
PRAME Immunohistochemical Expression in Recurrent/Traumatized Melanocytic Nevi and the Pitfall of Expression by
Emma Carraturo1, Giuseppe D'Abbronzo1, Giuseppe Argenziano2
1Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Introduction:
The recurrent/traumatized melanocytic nevus (RTMN) refers to melanocytic lesions that reappear following incomplete removal or trauma to a previous nevus, often presenting clinically and dermoscopically similar to melanoma, which complicates differential diagnosis. Histologically, RTMN exhibit melanocytic proliferation and scar tissue from prior trauma or excision. PRAME (preferentially expressed antigen in melanoma) immunohistochemistry (IHC) is emerging as a diagnostic tool for distinguishing between nevi, melanoma, and nevus-associated melanomas. However, its role in RTMN has not yet been established.
Objectives:
This study aimed to evaluate the expression of PRAME in RTMN, specifically in the melanocytic and fibroblastic components, to explore its potential diagnostic utility.
Methods:
A series of 22 RTMN cases from the Pathology Unit of the University of Campania Luigi Vanvitelli Hospital were reviewed. PRAME IHC was performed on formalin-fixed, paraffin-embedded tissue, and staining was evaluated in three compartments: junctional melanocytic, intradermal melanocytic, and fibroblastic scar tissue.
Results:
PRAME IHC showed no positivity in the junctional or intradermal melanocytic components of any case. However, five out of 22 cases (22.7%) demonstrated PRAME positivity in the fibroblastic component, which was statistically significant (P=0.0169).
Conclusions:
This study suggests that PRAME IHC is negative in the melanocytic components of RTMN, distinguishing it from melanoma. However, PRAME positivity in the fibroblastic scar component warrants careful interpretation to avoid diagnostic pitfalls. These findings emphasize the importance of considering the histological context when using PRAME as a diagnostic marker in RTMN.
Insights
PRAME immunohistochemistry (IHC) is negative in recurrent/traumatized melanocytic nevus (RTMN) melanocytes, aiding melanoma differentiation. However, PRAME positivity in fibroblastic scar tissue requires careful interpretation to avoid diagnostic errors.
Area of Science:
- Dermatopathology
- Immunohistochemistry
- Melanoma Diagnosis
Background:
- Recurrent/traumatized melanocytic nevus (RTMN) mimics melanoma, complicating diagnosis.
- PRAME immunohistochemistry (IHC) is a potential diagnostic marker for melanocytic lesions.
- The role of PRAME in RTMN remains unestablished.
Purpose of the Study:
- To evaluate PRAME expression in RTMN melanocytic and fibroblastic components.
- To assess PRAME's diagnostic utility in distinguishing RTMN from melanoma.
Main Methods:
- Review of 22 RTMN cases.
- PRAME IHC performed on formalin-fixed, paraffin-embedded tissues.
- Evaluation of PRAME staining in junctional melanocytic, intradermal melanocytic, and fibroblastic scar components.
Main Results:
- PRAME IHC was negative in all RTMN melanocytic components.
- PRAME positivity was observed in the fibroblastic scar component in 22.7% of cases (P=0.0169).
Conclusions:
- PRAME IHC negativity in RTMN melanocytes helps differentiate from melanoma.
- PRAME positivity in the fibroblastic component necessitates cautious interpretation.
- Histological context is crucial for accurate PRAME interpretation in RTMN.
